Aug 19, 2025
Cambridge Cognition Blog
Cambridge Cognition Blog Cambridge Cognition Investment, Monument Therapeutics, Announces Partnership with Foundation for the National Institutes of Health for Clinical Trial of MT1988, a Novel Treatment for Schizophrenia